1 but has not been reported for muscle in mitochondrial diseases. We describe a patient who presented with rapidly progressive, subacute muscle weakness due to a mitochondrial disorder.
A 38 year old woman presented for the first time with a sudden rapid progression over six weeks of myalgia at rest and muscle weakness. She became bedridden just before admission. On questioning she reported that for about a year she had some muscle pain and a very mild weakness, but continued with all her chores as a mother of six children.
Physical examination disclosed diffuse and pronounced muscle tenderness and moderate to severe proximal limb weakness (3/5 on the MRC scale), with normal strength distally. Tendon reflexes were hypoactive. She had no pyramidal signs and her mental functions, cranial nerves, sensation, and cerebellar functions were intact. The following laboratory tests were normal or negative: blood count, serum electrolytes, liver and renal function tests, arterial blood gases, antinuclear factor, complement concentration, serum protein electrophoresis, and thyroid hormone and cortisol concentrations. However, her erythrocyte sedimentation rate was accelerated (65/115), and serum creatine kinase concentrations were slightly raised (146 units, normal <110 units). Serum lactate concentration was high at rest (7.8 mM/l, normal <2.0 mM/l), and further increased during ischaemic exercise.
Electrodiagnostic evaluation disclosed a sensory polyneuropathy (conduction velocity of 32.9 m/s in the right sural nerve), with reduced recruitment, and some large amplitude, polyphasic units on EMG of the right quadriceps, tibialis anterior, and gastrocnemius muscles. Muscle biopsy disclosed many ragged-red fibres but no inflammation or myonecrosis. Electron microscopy confirmed the presence of abnormal mitochondria, some of which contained paracrystalline inclusions (figure). NADH cytochrome c oxydoreductase, ubiquinol/cytochrome c reductase and cytochrome c oxidase activities in muscle homogenate were 59 nmol/min/mg (10% of control values), 1.02 Bmol/min/mg (40% of control values), and 1.14 nmol/min/mg.
(20% of control values), respectively. DNA analysis for the common mutations of MERRF (tRNALys position 8344), MELAS (tRNALeu position 3243), and Kearns-Sayre syndrome (large deletions) was negative. Treatment with vitamin E (800 mg/day), vitamin C (2 g/day), ubiquinone (120 mg/day), and carnitine (330 mg/day) was initiated. A dramatic improvement of the patient's muscle strength ensued within a few weeks. Three months later only mild weakness without tenderness could be detected and the patient was stable, under treatment, throughout a year of follow up. She resumed her Few ragged-red fibres and mitochondrial morphological changes have been reported in inflammatory myopathies, including polymyositis, dermatomyositis, and inclusion body myositis, 2 3 and mitochondrial DNA abnormalities were recently described in patients with inclusion body myositis. 3 However, these changes are considered secondary and their pathophysiological role in the disease is unclear. The absence of any histological features of inflammation, necrosis, or rimmed vacuoles, the abnormalities of serum lactate concentrations, and the respiratory chain enzymatic abnormalities strongly suggest that our patient had a primary mitochondrial disorder.
Mitochondrial muscle disease usually follows a slowly progressive course attributed to dysfunction of oxidative metabolism and mitochondrial energy production. 1 The subacute presentation, accelerated course, myalgia, and raised erythrocyte sedimentation rate and creatine kinase concentrations are therefore very atypical for this disorder. What might be the mechanism of such an unusual course of a mitochondrial muscle disease? One explanation is that muscle destruction can induce a secondary immune process due to the continuous presentation of cytoplasmic or nuclear antigens to the immune system. Such a mechanism may account for the few reported cases 2 3 of pathological features of inflammatory myopathy with ragged-red fibres and mitochondrial DNA abnormalities. Nevertheless, muscle biopsies from our patients disclosed no inflammation, a finding that could have supported this theory.
An alternative possibility is that an accelerated necrotic process and the cell destruction in the muscle can result from an acute energy crisis. This is supported by the reported cases of myoglobinuria in mitochondrial disorders. 4 A similar but slower mechanism may explain the relatively rapid presentation in our patient, as well as the subacute mode of presentation of other mitochondrial disorders such as MELAS and LHON.
Although clinical improvement was previously reported in mitochondrial disorders after cofactor therapy, multiple complex deficiencies are associated with multisystem failure and early death. 5 A possible explanation for the pronounced improvement after treatment in our patient might be the threshold effect and the heteroplasmy phenomenon. 1 Theoretically, a critical subgroup of mitochondria with only a mild enzymatic defect may regain function after treatment with electron acceptors, the threshold for function is obtained and culminates in clinical improvement.
